Literature DB >> 30232742

First Conference on Big Data for Pharmacovigilance.

Jae Min1, Vicki Osborne2,3, Elizabeth Lynn2,3, Saad A W Shakir2,3.   

Abstract

Mesh：

Year:  2018        PMID： 30232742     DOI： 10.1007/s40264-018-0727-2

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  18 in total

1.  From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources.

Authors:  Gianluca Trifirò; Janet Sultana; Andrew Bate
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

2.  Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making.

Authors:  S Schneeweiss; H-G Eichler; A Garcia-Altes; C Chinn; A-V Eggimann; S Garner; W Goettsch; R Lim; W Löbker; D Martin; T Müller; B J Park; R Platt; S Priddy; M Ruhl; A Spooner; B Vannieuwenhuyse; R J Willke
Journal:  Clin Pharmacol Ther       Date:  2016-10-19       Impact factor: 6.875

3.  The druggable genome and support for target identification and validation in drug development.

Authors:  Chris Finan; Anna Gaulton; Felix A Kruger; R Thomas Lumbers; Tina Shah; Jorgen Engmann; Luana Galver; Ryan Kelley; Anneli Karlsson; Rita Santos; John P Overington; Aroon D Hingorani; Juan P Casas
Journal:  Sci Transl Med       Date:  2017-03-29       Impact factor: 17.956

4.  Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.

Authors:  Alexandra C Pacurariu; Sabine M Straus; Gianluca Trifirò; Martijn J Schuemie; Rosa Gini; Ron Herings; Giampiero Mazzaglia; Gino Picelli; Lorenza Scotti; Lars Pedersen; Peter Arlett; Johan van der Lei; Miriam C Sturkenboom; Preciosa M Coloma
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.606

Review 5.  Big data analytics in healthcare: promise and potential.

Authors:  Wullianallur Raghupathi; Viju Raghupathi
Journal:  Health Inf Sci Syst       Date:  2014-02-07

6.  An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.

Authors:  Tal Lorberbaum; Kevin J Sampson; Raymond L Woosley; Robert S Kass; Nicholas P Tatonetti
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

7.  Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.

Authors:  Samantha Lane; Elizabeth Lynn; Saad Shakir
Journal:  BMJ Open       Date:  2018-01-23       Impact factor: 2.692

8.  Methodology for computing the burden of disease of adverse events following immunization.

Authors:  Scott A McDonald; Danielle Nijsten; Kaatje Bollaerts; Jorgen Bauwens; Nicolas Praet; Marianne van der Sande; Vincent Bauchau; Tom de Smedt; Miriam Sturkenboom; Susan Hahné
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-03-24       Impact factor: 2.890

9.  An MCEM Framework for Drug Safety Signal Detection and Combination from Heterogeneous Real World Evidence.

Authors:  Cao Xiao; Ying Li; Inci M Baytas; Jiayu Zhou; Fei Wang
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

10.  Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data.

Authors:  Jenna M Reps; Martijn J Schuemie; Marc A Suchard; Patrick B Ryan; Peter R Rijnbeek
Journal:  J Am Med Inform Assoc       Date:  2018-08-01       Impact factor: 4.497
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.